Blog
RSS FeedPosted by Michael Wonder on 03 Apr 2024
Vertex announces new drug submission for exagamglogene autotemcel (exa-cel) has been accepted for priority review by Health Canada for the treatment of sickle cell disease and transfusion-dependent beta thalassaemia
1 April 2024 - Exa-cel is the first CRISPR-based gene-edited therapy to be submitted for Health Canada review. ...
Posted by Michael Wonder on 02 Apr 2024
Mirum Pharmaceuticals’ Livmarli (maralixibat oral solution) receives positive reimbursement recommendation by Canada’s CADTH for patients with cholestatic pruritus in Alagille syndrome
2 April 2024 - Positive HTA recommendation for reimbursement signifies an important milestone towards public funding to treat eligible patients with ...
Posted by Michael Wonder on 29 Mar 2024
Paladin Labs announces approval of Wakix (pitolisant hydrochloride tablets) for use in paediatric patients in Canada
28 March 2024 - Indication includes children ages 6 years and older and weighing at least 30 kg. ...
Posted by Michael Wonder on 26 Mar 2024
Cost and value of cancer medicines in a single payer public health system in Ontario, Canada: a cross-sectional study
26 March 2024 - We describe temporal trends in expenditure on cancer medicines within the single-payer health system of Ontario, Canada, ...
Posted by Michael Wonder on 21 Mar 2024
Health Canada accepts for review new drug submission for tofersen for treatment of rare, genetic form of ALS
19 March 2024 - Health Canada regulatory decision on tofersen new drug submission expected in early 2025. ...
Posted by Michael Wonder on 21 Mar 2024
Ferinject approved by Health Canada for the treatment of iron deficiency anaemia in adult and paediatric patients and iron deficiency in adult patients with heart failure
19 March 2024 - CSL Vifor today announced that Health Canada has authorised Ferinject (ferric carboxymaltose) for the intravenous treatment of ...
Posted by Michael Wonder on 15 Mar 2024
Bimzelx (bimekizumab) now approved for adults with active psoriatic arthritis and for adults with axial spondyloarthritis
14 March 2024 - Health Canada's approval is supported by Phase III clinical trial data which found Bimzelx provided significant improvement ...
Posted by Michael Wonder on 13 Mar 2024
Sumitomo Pharma announces availability of Orgovyx (relugolix) in Canada, the first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
12 March 2024 - Sumitomo Pharma announced today that Orgovyx (relugolix), an oral gonadotropin-releasing hormone receptor antagonist, is now available for ...
Posted by Michael Wonder on 06 Mar 2024
Wezlana (ustekinumab), a biosimilar to Stelara, now available in Canada for certain chronic inflammatory diseasee
4 March 2024 - Wezlana is the first biosimilar to Stelera to be available for Canadian patients in all indications. ...
Posted by Michael Wonder on 05 Mar 2024
AB Science today announces that Health Canada has issued a screening acceptance letter for the application of masitinib in the treatment of amyotrophic lateral sclerosis
9 May 2023 - AB Science today announces that Health Canada has issued a screening acceptance letter for ...
Posted by Michael Wonder on 05 Mar 2024
Nine drug formularies in Canada list Evenity for reimbursement for the treatment of osteoporosis in post-menopausal women as high risk of fracture
5 March 2024 - Multiple formulary listings are a step forward to ensuring that post-menopausal women have access to medicines ...
Posted by Michael Wonder on 04 Mar 2024
Findings from the Lean review of our drug reimbursement review program
29 February 2024 - Last year, CADTH communicated several improvements to our drug reimbursement review program, including a Lean review ...
Posted by Michael Wonder on 29 Feb 2024
Collaborating to help improve access to drugs for rare diseases
29 February 2024 - On Rare Disease Day — a day when the international community raises awareness about rare conditions ...
Posted by Michael Wonder on 28 Feb 2024
AB Science announces that Health Canada has issued a notice of non-compliance-withdrawal for masitinib in ALS
26 February 2024 - AB Science today announces that Health Canada has issued a notice of non-compliance-withdrawal regarding its new ...
Posted by Michael Wonder on 27 Feb 2024
GSK's RSV vaccine, Arexvy, accepted for review by Health Canada for prevention of RSV disease in adults aged 50-59 at increased risk
26 February 2024 - Submission supported by positive results of a Phase 3 study showing immune response and tolerability in adults ...